##### Table of Contents

---



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



---



FORM 10-Q/A



---



(Mark One)

|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------



For the quarterly period ended September 30, 2005



or



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------



For the transition period from
 to



Commission File Number: 000-19122



---



APHTON CORPORATION

(Exact name of registrant as specified in its charter)



---



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 95-3640931                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
|                                                               | 
|8 Penn Center, 1628 JFK Boulevard, Suite 2300 Philadelphia, PA |  | 19103                               
|(Address of principal executive offices)                       |  | (Zip Code)                          



(215) 218-4340

(Registrants telephone number, including area code)





---

(Former name, former address and former fiscal year, if changed since last report)



---



Indicate by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. x Yes ̈No



Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). x Yes ̈No



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ̈Yes  x No



Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date:



|                               |  |                             |  |                 
|------------------------------ |  | --------------------------- |  | ----------------
|Class                          |  | Number ofShares outstanding |  | As of           
|Common Stock, $0.001 par value |  | 60,556,428                  |  | November 9, 2005



---



---

##### Table of Contents

EXPLANATORY NOTE



This Amendment No. 1 on Form 10Q/A (the Amendment) amends the Quarterly Report on Form 10Q for the
quarter ended September 30, 2005 (the Original Report) of Aphton Corporation (the Company). As reported in the Current Report on Form 8K filed by the Company, on November 22, 2005, the Audit Committee of the
Companys Board of Directors determined that the Companys consolidated financial statements included in the Original Report and the Companys Quarterly Report on Form 10Q for the quarter ended June 30, 2005 should be restated
to reclassify certain of our liabilities from other liabilities (long-term) to various current liability accounts (including current-portion of long-term liabilities, trade accounts payable and accrued liabilities), to make certain balance sheet
adjustments to reflect the issuance of stock in lieu of cash interest payments on our 2003 Senior Convertible Notes and the over-accrual of interest, to revise the required supplemental disclosures regarding our Austrian subsidiarys
liabilities, to roll-forward the effect of revisions made to the Companys consolidated financial statements included in the Companys 10-Q/A for the period ended June 30, 2005 and to restate the Statement of Cash Flows to reflect these
adjustments.



The restated consolidated financial statements
for the quarter ended September 30, 2005 included in the Amendment (the Restatement) reflect (i) a reclassification of $4.3 million in long-term liabilities to current liabilities and (ii) a reduction of $0.45 million in accrued interest
payable to reflect the roll forward impact of a $0.3 million reduction for the second quarter of 2005 related to the issuance of common stock in lieu of interest on our 2003 Senior Convertible Notes and a $0.15 million adjustment due to an excess
accrual. As a result of these adjustments, (1) current liabilities increased from $19.3 million in the Original Report to $23.3 million in this Amendment, (2) accrued interest payable decreased from $0.75 million in the Original Report to $0.3
million in this Amendment, (3) long-term liabilities decreased from $17.9 million in the Original Report to $13.6 million in this Amendment, (4) additional paid-in-capital increased from $244.2 million in the Original Report to $244.5 million in
this Amendment and (5) Total Stockholders Deficit decreased from $12.6 million in the Original Report to $12.3 million in this Amendment. See Note 4 of the Notes to Financial Statements included in the Amendment. The Amendment amends and
restates Items 1, 2, 3 and 4 of Part I and Item 6 of Part II of the Original Report to the extent necessary to reflect the effects of the Restatement. Except for such amendments, the Amendment continues to describe conditions as of the date of the
Original Report, and the Company has not modified or updated other disclosures presented in the Original Report affected by subsequent events. Accordingly, the Amendment should be read in conjunction with the Original Report and the Companys
filings made with the Securities and Exchange Commission subsequent to the filing of the Original Report.



APHTON CORPORATION



Index



|                               |  |                                                                                                             |  |     
|------------------------------ |  | ----------------------------------------------------------------------------------------------------------- |  | ----
|                               |  |                                                                                                             |  | Page
|Part I  Financial Information |  | 1                                                                                                          
|                               |  |                                                                                                            
|Item 1.                        |  | Financial Statements:                                                                                       |  | 1   
|                               |  |                                                                                                            
|                               |  | Consolidated Balance Sheets  September 30, 2005, (unaudited) and December 31, 2004                         |  | 2   
|                               |  |                                                                                                            
|                               |  | Consolidated Statements of Operations (unaudited)  Three and nine months ended September 30, 2005 and 2004 |  | 3   
|                               |  |                                                                                                            
|                               |  | Consolidated Statements of Cash Flows (unaudited)  Nine months ended September 30, 2005 and 2004           |  | 4   
|                               |  |                                                                                                            
|                               |  | Notes to Consolidated Financial Statements (unaudited)                                                      |  | 5   
|                               |  |                                                                                                            
|Item 2.                        |  | Managements Discussion and Analysis of Financial Condition and Results of Operations                       |  | 11  
|                               |  |                                                                                                            
|Item 3.                        |  | Quantitative and Qualitative Disclosures About Market Risk                                                  |  | 19  
|                               |  |                                                                                                            
|Item 4.                        |  | Controls and Procedures                                                                                     |  | 20  
|                               | 
|Part II  Other Information    |  | 21                                                                                                         
|                               |  |                                                                                                            
|Item 6.                        |  | Exhibits                                                                                                    |  | 21  
|                               | 
|Signatures                     |  | 22                                                                                                         



i



---

##### Table of Contents

Part I - Financial Information



|Item 1. | Financial Statements
|------- | --------------------



The interim consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the
Securities and Exchange Commission. In the opinion of management, the consolidated financial statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position as of September 30,
2005, and December 31, 2004, and the results of our operations for the three and nine months ended September 30, 2005 and 2004; and our cash flows for the nine months ended September 30, 2005 and 2004. These financial statements
should be read in conjunction with the consolidated financial statements and the notes thereto included in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2005.



1



---

##### Table of Contents

APHTON CORPORATION

Consolidated Balance Sheets



|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ------------------ | ------------ | - | ----------------- | - | ------------ | -
|                                                                                                                                                                             |  | September 30, 2005 |              |   | December 31, 2004 |  
|                                                                                                                                                                             |  | (Unaudited)        |              |   |                   |  
|Assets                                                                                                                                                                       |  |                    |              |   |                   |   |              |  
|Current assets:                                                                                                                                                              |  |                    |              |   |                   |   |              |  
|Cash and cash equivalents                                                                                                                                                    |  | $                  | 8,711,370    |   |                   | $ | 29,999,497   |  
|Short-term investments available for sale                                                                                                                                    |  |                    | 6,115,115    |   |                   |   | 12,314,992   |  
|Investment securities-trading                                                                                                                                                |  |                    |             |   |                   |   | 1,099,585    |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Total cash and short-term equivalents                                                                                                                                        |  |                    | 14,826,485   |   |                   |   | 43,414,074   |  
|Other current assets                                                                                                                                                         |  |                    | 2,103,033    |   |                   |   | 556,165      |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Total current assets                                                                                                                                                         |  |                    | 16,929,518   |   |                   |   | 43,970,239   |  
|Equipment and improvements, net                                                                                                                                              |  |                    | 461,979      |   |                   |   | 780,307      |  
|Deferred financing costs, net                                                                                                                                                |  |                    | 466,950      |   |                   |   | 519,915      |  
|Unconditional supply commitment                                                                                                                                              |  |                    | 6,704,678    |   |                   |   | 6,704,678    |  
|Other assets                                                                                                                                                                 |  |                    |             |   |                   |   | 659,488      |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Total assets                                                                                                                                                                 |  | $                  | 24,563,125   |   |                   | $ | 52,634,627   |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Liabilities and Stockholders Equity (deficit)                                                                                                                               |  |                    |              |   |                   |   |              |  
|Liabilities                                                                                                                                                                  |  |                    |              |   |                   |   |              |  
|Current liabilities:                                                                                                                                                         |  |                    |              |   |                   |   |              |  
|Convertible debentures, net                                                                                                                                                  |  | $                  | 9,872,848    |   |                   | $ |             |  
|Trade accounts payable                                                                                                                                                       |  |                    | 4,103,936    |   |                   |   | 3,941,760    |  
|Due to related party                                                                                                                                                         |  |                    | 1,860,000    |   |                   |   | 3,255,435    |  
|Accrued liabilities                                                                                                                                                          |  |                    | 2,839,541    |   |                   |   | 1,835,006    |  
|Current portion of long-term liabilities                                                                                                                                     |  |                    | 4,328,804    |   |                   |   |             |  
|Accrued interest payable                                                                                                                                                     |  |                    | 300,000      |   |                   |   | 630,000      |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Total current liabilities                                                                                                                                                    |  |                    | 23,305,129   |   |                   |   | 9,662,201    |  
|Convertible debentures, net                                                                                                                                                  |  |                    |             |   |                   |   | 11,845,022   |  
|Deferred revenue                                                                                                                                                             |  |                    | 10,000,000   |   |                   |   | 10,000,000   |  
|Other liabilities                                                                                                                                                            |  |                    | 3,603,518    |   |                   |   | 137,247      |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Total liabilities                                                                                                                                                            |  | $                  | 36,908,647   |   |                   | $ | 31,644,470   |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Commitments and contingencies                                                                                                                                                |  |                    |              |   |                   |   |              |  
|Stockholders equity (deficit):                                                                                                                                              |  |                    |              |   |                   |   |              |  
|Preferred stock, $0.001 par value  Authorized: 4,000,000 shares; Issued and outstanding: none                                                                               |  | $                  |             |   |                   | $ |             |  
|Common stock, $0.001 par value  Authorized: 100,000,000 shares; Issued and outstanding: 60,051,728 shares at September 30, 2005,
and 37,798,586 shares at December 31, 2004 |  |                    | 60,052       |   |                   |   | 37,799       |  
|Additional paid in capital                                                                                                                                                   |  |                    | 244,496,169  |   |                   |   | 216,320,552  |  
|Historical exchange rate account                                                                                                                                             |  |                    | 582,520      |   |                   |   |             |  
|Purchase warrants                                                                                                                                                            |  |                    | 298,900      |   |                   |   | 298,900      |  
|Accumulated deficit                                                                                                                                                          |  |                    | (257,783,163 | ) |                   |   | (195,667,094 | )
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Total stockholders equity (deficit)                                                                                                                                         |  |                    | (12,345,522  | ) |                   |   | 20,990,157   |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  
|Total liabilities and stockholders equity (deficit)                                                                                                                         |  | $                  | 24,563,125   |   |                   | $ | 52,634,627   |  
|                                                                                                                                                                             |  |                    |              |   |                   |   |              |  



The accompanying
notes are an integral part of the financial statements.



2



---

##### Table of Contents

APHTON CORPORATION

Consolidated Statements of Operations (Unaudited)

For the three and nine months ended September 30, 2005 and 2004



|                                                     |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|---------------------------------------------------- |  | -------------------------------- | ---------- | - | ------------------------------- | - | ---------- | ---- |  | - | ----------- | - |  | - | ----------- | -
|                                                     |  | Three months ended September 30, |            |   | Nine months ended September 30, |  
|                                                     |  | 2005                             |            |   | 2004                            |   |            | 2005 |  |   | 2004        |  
|Revenue:                                             |  | $                                |           |   |                                 | $ |           |      |  | $ |            |   |  | $ |            |  
|                                                     |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Costs and expenses:                                  |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|General and administrative                           |  | $                                | 3,145,657  |   |                                 | $ | 935,262    |      |  | $ | 8,499,750   |   |  | $ | 2,597,393   |  
|Research and development                             |  |                                  | 4,582,162  |   |                                 |   | 5,813,667  |      |  |   | 17,729,582  |   |  |   | 15,977,851  |  
|Acquired in-process research and development         |  |                                  |           |   |                                 |   |           |      |  |   | 32,991,860  |   |  |   |            |  
|Restructuring expense, net                           |  |                                  | 288,333    |   |                                 |   |           |      |  |   | 1,106,455   |   |  |   |            |  
|                                                     |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Total costs and expenses                             |  |                                  | 8,016,152  |   |                                 |   | 6,748,929  |      |  |   | 60,327,647  |   |  |   | 18,575,244  |  
|                                                     |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Loss from operations                                 |  |                                  | (8,016,152 | ) |                                 |   | (6,748,929 | )    |  |   | (60,327,647 | ) |  |   | (18,575,244 | )
|Other income (expense):                              |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Dividend and interest income                         |  |                                  | 92,755     |   |                                 |   | 224,046    |      |  |   | 636,068     |   |  |   | 368,177     |  
|Interest expense including amortized discount        |  |                                  | (830,885   | ) |                                 |   | (677,457   | )    |  |   | (2,424,488  | ) |  |   | (1,976,858  | )
|Unrealized gain (losses) from investments            |  |                                  | 23,122     |   |                                 |   | (30,558    | )    |  |   |            |   |  |   | (20,310     | )
|                                                     |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Net loss                                             |  | $                                | (8,731,160 | ) |                                 | $ | (7,232,898 | )    |  | $ | (62,116,067 | ) |  | $ | (20,204,235 | )
|                                                     |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Per share data:                                      |  |                                  |            |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Basic and fully diluted loss per common share        |  | $                                | (0.14      | ) |                                 | $ | (0.19      | )    |  | $ | (1.17       | ) |  | $ | (0.56       | )
|Weighted average number of common shares outstanding |  |                                  | 60,447,978 |   |                                 |   | 37,711,850 |      |  |   | 53,299,924  |   |  |   | 35,775,722  |  



The accompanying
notes are an integral part of the financial statements.



3



---

##### Table of Contents

APHTON CORPORATION

Consolidated Statements of Cash Flows (Unaudited)

For the nine months ended September 30, 2005 and 2004



|                                                                            |  |                                 |             |   |      |   |             |  
|--------------------------------------------------------------------------- |  | ------------------------------- | ----------- | - | ---- | - | ----------- | -
|                                                                            |  | Nine Months Ended September 30, |            
|                                                                            |  | 2005                            |             |   | 2004 |  
|Net cash used in operating activities                                       |  | $                               | (25,081,575 | ) |      | $ | (18,260,702 | )
|                                                                            |  |                                 |             |   |      |   |             |  
|Net cash provided by (used in) operating activities                         |  |                                 | (25,081,575 | ) |      |   | (18,260,702 | )
|                                                                            |  |                                 |             |   |      |   |             |  
|Cash flows from investing activities:                                       |  |                                 |             |   |      |   |             |  
|Investment securities  available for sale                                  |  |                                 | 6,199,876   |   |      |   |            |  
|Cash acquired in acquisition, net of cost                                   |  |                                 | 1,459,423   |   |      |   |            |  
|Capital expenditures                                                        |  |                                 | (114,639    | ) |      |   | (293,381    | )
|                                                                            |  |                                 |             |   |      |   |             |  
|Net cash provided by (used in) investing activities                         |  |                                 | 7,544,660   |   |      |   | (293,381    | )
|                                                                            |  |                                 |             |   |      |   |             |  
|Cash flows from financing activities:                                       |  |                                 |             |   |      |   |             |  
|Proceeds from sale of common stock and warrants                             |  |                                 | 652         |   |      |   | 48,624,188  |  
|Payment on notes                                                            |  |                                 | (3,751,864  | ) |      |   |            |  
|                                                                            |  |                                 |             |   |      |   |             |  
|Net cash provided by (used in) financing activities                         |  |                                 | (3,751,212  | ) |      |   | 48,624,188  |  
|                                                                            |  |                                 |             |   |      |   |             |  
|Net (decrease) increase in cash and short-term cash investments             |  |                                 | (21,288,127 | ) |      |   | 30,070,105  |  
|Cash and cash equivalents:                                                  |  |                                 |             |   |      |   |             |  
|Beginning of period                                                         |  | $                               | 29,999,497  |   |      | $ | 18,378,988  |  
|                                                                            |  |                                 |             |   |      |   |             |  
|End of period                                                               |  | $                               | 8,711,370   |   |      | $ | 48,449,093  |  
|                                                                            |  |                                 |             |   |      |   |             |  
|Reconciliation of net loss to net cash used in operating activities         |  |                                 |             |   |      |   |             |  
|Net loss                                                                    |  | $                               | (62,116,068 | ) |      | $ | (20,204,235 | )
|                                                                            |  |                                 |             |   |      |   |             |  
|Adjustments to reconcile net loss to net cash used in operating activities: |  |                                 |             |   |      |   |             |  
|Charges for acquired in-process research and development and other          |  |                                 | 32,991,860  |   |      |   |            |  
|Common stock issued for interest payment                                    |  |                                 | 750,207     |   |      |   | 900,000     |  
|Interest expense to be settled by future issuance of common stock           |  |                                 | 300,000     |   |      |   |            |  
|Depreciation and amortization                                               |  |                                 | 610,822     |   |      |   | 54,664      |  
|Amortization of deferred financing costs                                    |  |                                 | 52,965      |   |      |   | 23,885      |  
|Amortization of discount on convertible debentures                          |  |                                 | 1,041,617   |   |      |   | 804,697     |  
|Unrealized gain/loss on investments                                         |  |                                 |            |   |      |   | 20,310      |  
|Non-cash employee compensation expense                                      |  |                                 |            |   |      |   | (20,310     | )
|Change in historical exchange rate account                                  |  |                                 | 582,519     |   |      |   |            |  
|Investment securities                                                       |  |                                 | 7,591,178   |   |      |   | (144,091    | )
|Other current assets                                                        |  |                                 | 381,054     |   |      |   | (141,127    | )
|Current liabilities                                                         |  |                                 | (3,104,023  | ) |      |   | 445,505     |  
|Additional Paid in Capital                                                  |  |                                 | 499,421     |   |      |   |            |  
|Other non-current liabilities                                               |  |                                 | (4,663,127  | ) |      |   |            |  
|                                                                            |  |                                 |             |   |      |   |             |  
|Net cash used in operating activities:                                      |  | $                               | (25,081,575 | ) |      | $ | (18,260,702 | )
|                                                                            |  |                                 |             |   |      |   |             |  



The accompanying
notes are an integral part of the financial statements.



4



---

##### Table of Contents

Notes to the Consolidated Financial Statements (unaudited)



1. Organization and Summary of Significant Accounting Policies



Aphton Corporation (Aphton or the Company) is a biopharmaceutical company focused on developing innovative cancer therapies. The Companys research and development efforts are based on its
proprietary active immunization and monoclonal antibody technologies, and its technologies are based on key discoveries made by it as well as its understanding of the central role of gastrin, a naturally occurring hormone, and gastrin receptors.



On March 24, 2005, Aphton completed the acquisition of
Igeneon AG, a clinical stage biopharmaceutical company headquartered in Vienna, Austria. Through Igeneon, Aphton is focused on the development of active and passive cancer immunotherapies (cancer vaccines and monoclonal antibodies) designed to
prevent or delay the development of metastases in cancers of epithelial origin. These product candidates are designed to target disseminated tumor cells, thereby having the potential to prevent metastasis and the spread of cancer.



The Company does not currently have any source of operating revenue and will
require significant amounts of cash to continue to fund its operations, its clinical trials and its research and development efforts until such time, if ever, that one of its products has received regulatory approval for marketing. Because the
Company has not generated any revenue from the sale of any products, the Company has primarily relied on the capital markets as its source of funding. The results of the Companys recent Insegia clinical trial and other factors have weakened
the market value of its common stock, and made it difficult for the Company to access the capital markets to obtain financing on terms that would benefit the Company in the long term. However, because the Company has recently entered into an
agreement with the holders of the Companys Senior Convertible Notes to exchange the notes for a combination of cash, preferred stock and common stock, the Company will continue to be opportunistic in accessing the capital markets to obtain
financing on terms satisfactory to the Company. In addition, the Company continues to explore a number of alternatives, including licensing or selling a significant portion or all of its intellectual property and/or other assets, the sale or
exchange of a significant portion or all of its equity, or pursuing other financing alternatives. The Company may implement one or more of these alternatives. If the Company is successful in obtaining any financing, the Company intends to use the
net proceeds it receives from the financing to fund its operations and support the clinical development of its product candidates. No assurances, however, can be given that the Company will close the exchange transaction for its Senior Convertible
Notes, consummate a capital raise on terms satisfactory to the Company or that any particular strategic transaction will be completed, nor can any prediction or assurance be made regarding the possible impact of future transactions on the
Companys business, results or capitalization. The Companys ability to consummate the exchange of its 2003 Senior Convertible Notes, make interest or principal payments on its indebtedness, comply with the covenants in its indebtedness
documents, or effectively implement any of the above-mentioned alternatives to fund its future operations is dependent on many factors, many of which are beyond the Companys control.



Interim Financial Statements



The interim consolidated financial statements included herein have been
prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the consolidated financial statements include all adjustments (consisting of normal recurring
entries) necessary to present fairly the Companys financial position as of September 30, 2005, and December 31, 2004, and the results of its operations for the three and nine months ended September 30, 2005 and 2004; and its
cash flows for the nine months ended September 30, 2005 and 2004. It is suggested that these financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Companys latest
annual report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2005.



Use of Estimates in the Preparation of Financial Statements



The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.



Research and
Development Expenses



Research and development costs
are expensed as incurred. These costs include external and internal research and development costs, the salaries of dedicated personnel, the allocated salaries of personnel who also perform general and administrative tasks, the costs of the
dedicated research and development facilities and the costs of contracted researchers. There is no allocation of administrative expense or corporate costs to research and development costs.



5



---

##### Table of Contents

Foreign Currency Accounting



The Company complies withStatement of Financial Accounting (SFAS) No. 52 Foreign Currency Translation,which established standards for reporting on foreign subsidiaries in consolidated financial statements.



General and Administrative Expenses



General and administrative expenses represent expenses not clearly related to research and development expenses. A significant portion of these expenses are related to intellectual property/patent legal costs and
salaries, which are typically excluded from research and development expenses according to SFAS No. 2 Accounting for Research and Development Costs.



Supply Commitment



As of September 30, 2005, in connection with its strategic alliance with sanofi pasteur, the Company had the unconditional right to receive supplies
originally aggregating $9 million from sanofi pasteur. The Companys policy was to review the current market prices of alternative available supplies, if any, to assure that they remain above the stated sanofi pasteur contract price of the
materials and that the right to receive the supplies remains unimpaired. Sanofi pasteur is one of the largest pharmaceutical vaccine manufacturers in the world. The Company monitored the financial performance of sanofi pasteur to assess whether it
would continue to be able to perform under the contract, wherein the special order supplies were to be provided from supplies manufactured by sanofi pasteur in large quantities and sold to many customers, including the U.S. Government, as part of
sanofi pasteur basic franchise business. The contract allowed for inflation-based increases in the per unit costs of the supplies which the Company and sanofi pasteur believed were sufficient to assure that there would be no future financial
hardship incurred by sanofi pasteur in the execution of the agreement with sanofi pasteur, including the supply agreement. The Company has recently entered into a termination agreement terminating its strategic alliance. For a more detailed
description of the terms of the termination agreement, see Note 6, Subsequent Events.



Per Share Data



The Companys
basic loss per common share was calculated by dividing net loss by the weighted average number of common shares outstanding. The Companys potential common shares are anti-dilutive, and accordingly, basic and diluted loss per share are the
same. Such potential common shares consist of stock options and purchase warrants.



Investments



Investment securities
consist principally of debt securities issued by the U.S. Treasury and other U.S. Government agencies and corporations and investment in other securities, including mutual funds.



Investment securities are classified into three categories and accounted for as follows: 1) Held-to-maturity securities are
debt securities that the Company has the positive intent and ability to hold to maturity (these securities are reported at amortized cost); 2) trading securities are bought and held principally for the purpose of selling them in the near term (these
securities are reported at fair value, with unrealized gains and losses included in current earnings); and 3) investment securities available for sale are debt and equity securities not classified as either held-to-maturity or trading securities.



The Company did not hold any held-to-maturity securities at
September 30, 2005, and December 31, 2004. Investment securities available for sale are carried at market value and any unrealized gain or loss, net of income taxes, is reported in accumulated other comprehensive income as a separate
component of stockholders equity (deficit). Gains and losses realized on the sales of investment securities are determined using the specific identification method.



Comprehensive Income



The Company complies with SFAS No. 130, Reporting Comprehensive Income, which established standards for reporting comprehensive income
(defined to include net income, unrealized gains and losses on available-for-sale investment securities, foreign currency adjustments and certain other items not included in the income statement). The Company does not have elements of other
comprehensive income other than net loss, an historical exchange account for foreign currency transactions and unrealized gains and losses on available-for-sale investment securities.



Stock-Based Compensation



SFAS No. 148, Accounting for Stock-Based Compensation allows either adoption of a fair value based method of accounting for employee
stock options and similar equity instruments or continuation of the measurement of compensation cost relating to such plans using the intrinsic value method of accounting prescribed by Accounting Principles Board (APB) Opinion No. 25,
Accounting for Stock Issued to Employees. The Company has elected to use the intrinsic value method.



6



---

##### Table of Contents

Pro forma information is required by SFAS No. 148 and has been determined as if the Company had
accounted for its stock-based compensation plans under the fair value method. The fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used
for grants in 2005 and 2004: risk-free interest rates of 3.0%; dividend yield of 0% for all periods; expected volatility factor of 100% for all periods; and expected weighted average life of 19.5 years. The weighted average fair value of options
granted during 2005 and 2004 was $1.09 and $6.45, respectively. Additionally, there were 70,000 shares of restricted stock issued to Company directors on April 21, 2005, which vested the same day. The per share price of these restricted
issuances was $1.08 and the total value of these shares was $75,600.



The Companys pro forma information follows for the three and nine months ended September 30, 2005 and 2004, respectively:



|                                  |  |                                  |             |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|--------------------------------- |  | -------------------------------- | ----------- | - | ------------------------------- | - | ---------- | ---- |  | - | ----------- | - |  | - | ----------- | -
|                                  |  | Three months ended September 30, |             |   | Nine months ended September 30, |  
|                                  |  | 2005                             |             |   | 2004                            |   |            | 2005 |  |   | 2004        |  
|Net Loss:                         |  |                                  |             |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|As reported                       |  | $                                | (8,731,161  | ) |                                 | $ | (7,232,898 | )    |  | $ | (62,116,068 | ) |  | $ | (20,204,235 | )
|Compensation expense              |  |                                  | (1,360,408  | ) |                                 |   | (320,626   | )    |  |   | (3,567,674  | ) |  |   | (1,618,704  | )
|                                  |  |                                  |             |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Pro forma                         |  | $                                | (10,091,569 | ) |                                 | $ | (7,553,524 | )    |  | $ | (65,683,742 | ) |  | $ | (21,822,939 | )
|                                  |  |                                  |             |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Basic and diluted loss per share: |  |                                  |             |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|As reported                       |  | $                                | (0.14       | ) |                                 | $ | (0.19      | )    |  | $ | (1.17       | ) |  | $ | (0.56       | )
|Compensation expense              |  | $                                | (0.02       | ) |                                 | $ | (0.01      | )    |  | $ | (0.07       | ) |  | $ | (0.05       | )
|                                  |  |                                  |             |   |                                 |   |            |      |  |   |             |   |  |   |             |  
|Pro forma                         |  | $                                | (0.16       | ) |                                 | $ | (0.20      | )    |  | $ | (1.24       | ) |  | $ | (0.61       | )
|                                  |  |                                  |             |   |                                 |   |            |      |  |   |             |   |  |   |             |  



Recent Accounting Pronouncements



In December 2004, the FASB issued SFAS
No. 123(R), Share-Based Payments, which establishes standards for transactions in which an entity exchanges its equity instruments for goods or services. This standard requires a public entity to measure the costs of employee
services received in exchange for an award of equity instruments based on the grant-date fair value of the award. This eliminates the exception to account for such awards using the intrinsic method previously allowable under APB Opinion No. 25.
SFAS No. 123(R) will be effective for the Company beginning January 1, 2006. We are in the process of evaluating the impact of this standard on our financial statements. We will apply the modified prospective transition method
and implement the provisions of SFAS No. 123(R) beginning in the first quarter of 2006. The Company currently accounts for such awards using the intrinsic method currently allowable under APB Opinion No. 25.



2. March 2005 Acquisition for Common Stock



On March 24, 2005, the Company acquired all of the outstanding equity
interests of Igeneon AG, a company based in Vienna, Austria. The results of operations of Igeneon have been included in the consolidated financial statements since March 24, 2005. The aggregate purchase price for the acquisition was 21,500,000
shares of Aphton common stock and $25,000 in cash. The Company obtained an appraisal from an independent third party to estimate the fair value of the identified intangible assets acquired. Based on the consideration provided, the acquisition of
Igeneon resulted in negative goodwill, which has been allocated, on a pro-rata basis, to the acquired technology and acquired property and equipment and then expensed as acquired in-process research and development.



As part of the preliminary purchase price allocation, the Company allocated
$33.0 million of the purchase price to in-process research and development projects. This allocation represented the estimated fair value based on risk-adjusted cash flows pertaining to the incomplete research and development related primarily to
two projects. At the date of acquisition, the development of these projects had not yet reached technological feasibility and the research and development in progress had no alternative future uses. Accordingly, the acquired research and development
was charged to expense as of the date of acquisition.



3. Convertible
Notes/Debentures



As of December 31, 2004, the
Company had an aggregate principal amount of $23.0 million of convertible debentures and notes outstanding. The $23.0 million principal amount was comprised of $20.0 million of the 2003 Senior Convertible Notes and $3.0 million of the Companys
Series A Convertible Debenture (the Series A Convertible Debenture). The Series A Convertible Debenture was a convertible, redeemable, five-year debenture that would mature on December 19, 2007. At any time prior to maturity, the
Company had the right to redeem the Series A Convertible Debenture. In addition, at any time prior to maturity, the Company had the obligation to redeem the Series A Convertible Debenture under certain conditions, including if the Company
transferred its rights to certain projects or other products, or any other rights related thereto, to any entity, other than the holder of the Series A Convertible Debenture or its affiliates. The Series A Convertible Debenture bore interest at a
rate of 11.0% per annum, payable annually and was convertible, at the holders option, at a conversion price equal to the average closing price of the Companys common stock, as defined in the Series A Convertible Debenture, at the time of
conversion. In connection with the dissolution of the Companys strategic partnership with sanofi pasteur, the Company redeemed the Series A Convertible Debenture in August 2005.



As of September 30, 2005, and December 31, 2004, the Company had an aggregate principal amount of $20.0 million of
convertible notes outstanding. The $20.0 million was comprised of three senior convertible notes issued by the Company in 2003 (the 2003 Senior Convertible Notes). There was an initial discount calculated against the value of the 2003
Senior Convertible Notes of $12.9 million, comprised of the beneficial conversion feature of $8.3 million and the relative fair value of the detachable warrants of $4.6 million. The unamortized discount as of September 30, 2005, is $10.1
million, which is offset against the $20.0 million and is shown as $9.9 million in the 2003 Senior Convertible Notes in the accompanying financial statements.





7



---

##### Table of Contents

The $20.0 million in 2003 Senior Convertible Notes were issued in two tranches to accredited investors
during the six months ended June 30, 2003. The 2003 Senior Convertible Notes mature on March 31, 2008. We have the right and obligation to redeem the 2003 Senior Convertible Notes under certain conditions at any time after the third year
from the issuance date. The 2003 Senior Convertible Notes bear interest at a rate of 6.0% per annum, payable quarterly in cash or shares of the Companys common stock, at the Companys option.



The 2003 Senior Convertible Notes are convertible at a fixed price of $2.50
per share, unless otherwise adjusted prior to conversion pursuant to the price adjustment provisions set forth therein. The conversion price of the 2003 Senior Convertible Notes will be lowered in the event of a sale by the Company of its common
stock or securities convertible into the Companys common stock at a per share offering price less than the conversion price of the 2003 Senior Convertible Notes in effect immediately prior to such sale. The warrants are exercisable into shares
of the Companys common stock at $2.70 per share, unless otherwise adjusted prior to exercise pursuant to the price adjustment provisions that are substantially similar to those set forth in the 2003 Senior Convertible Notes. The 2003 Senior
Convertible Notes and the warrants contain provisions that place a cap on the number of shares of our common stock issuable upon their conversion or exercise, such that the holders thereof shall not have the right to convert any portion of the notes
to the extent that after giving effect to such conversion the holders would beneficially own more than 19.99% or 4.99%, as the case may be for the respective holder, of the number of shares of the Companys common stock outstanding immediately
prior to such conversion or exercise.



On November 9,
2005, the Company entered into an a binding Letter Agreement with the holders of the 2003 Senior Convertible Notes, whereby the holders agreed to surrender the notes for cancellation by the Company in exchange for an aggregate cash payment of
3.0 million, shares of the Companys 0% Non-participating Series A-1 Convertible Preferred Stock with an original Stated Value of $10 million and 6,500,000 shares of the Companys common stock. For more details on the terms of the
debt cancellation, see Note 6, Subsequent Events.



4. Other Financial
Liabilities



As of September 30, 2005, reflected on
the balance sheet were current portion of long-term liabilities of $4,329,000 and non-current other liabilities of $3,604,000. The total of these balance sheet line items is $7,933,000. Of this balance, the Companys wholly-owned subsidiary,
Igeneon, had outstanding an aggregate of $7,695,000 in interest-bearing liabilities and finance lease obligations, details of which are noted in the tables below.



|                             |  |                  |       |                  |   |       |  |   |      
|---------------------------- |  | ---------------- | ----- | ---------------- | - | ----- |  | - | -----
|                             |  | Less than 1 year |       | More than 1 year |   | Total
|Interest-bearing liabilities |  | $                | 3,957 |                  | $ | 2,950 |  | $ | 6,907
|Finance leasing obligations  |  |                  | 372   |                  |   | 416   |  |   | 788  
|                             |  |                  |       |                  |   |       |  |   |      
|Total                        |  | $                | 4,329 |                  | $ | 3,366 |  | $ | 7,695
|                             |  |                  |       |                  |   |       |  |   |      



The interest-bearing
liabilities are comprised of financial liabilities relating to funds received by Igeneon prior to the acquisition of Igeneon by the Company from various financial institutions and guaranteed by governmental agencies for Igeneons research and
development activities. Further, the interest rates on the loans are subsidized by government research incentive programs. The table below provides the amounts in principal and interest outstanding (in thousands in USD Equivalents), the maturity of
each liability and the interest rate.



|                                                          |  |             |       |          |                |               |                  |  
|--------------------------------------------------------- |  | ----------- | ----- | -------- | -------------- | ------------- | ---------------- | -
|Institution                                               |  | Outstanding |       | Maturity |                | Interest rate |                 
|Österreichische Forschungsförderungs-gesellschaft (EUR)   |  | $           | 562   |          | June 30, 2006  |               | 3.0              | %
|Bank Austria Creditanstalt (ERP-Investitionskredit) (EUR) |  | $           | 2,714 |          | July 1, 2006   |               | 0.5              | %
|Bank Austria Creditanstalt (FFG-Investitionskredit) (EUR) |  | $           | 883   |          | June 30, 2007  |               | 3-m.EURIBOR +0.6 | %
|Erste Bank (FFG-Kredit) (EUR)                             |  | $           | 482   |          | March 31, 2008 |               | 3-m.EURIBOR +0.6 | %
|Bank Austria Creditanstalt (FFG-Kredit) (EUR)             |  | $           | 1,061 |          | June 30, 2009  |               | 3-m.EURIBOR +0.5 | %
|Erste Bank (AWS-Kredit) (EUR)                             |  | $           | 1,205 |          | July 1, 2010   |               | 3-m.EURIBOR +0.5 | %
|                                                          |  |             |       |          |                |               |                  |  
|Total                                                     |  | $           | 6,907 |          |                |               |                  |  
|                                                          |  |             |       |          |                |               |                  |  



8



---

##### Table of Contents

5. Restructuring



On May 11, 2005, the Company announced that it was implementing a cost-reduction program intended to align expenses with product development
priorities. As of September 30, 2005, 27 employees have been terminated. The restructuring charge taken at September 30, 2005, was $1,106,000. Included in this amount is $1,085,000 for severance, and $51,000 for other professional
services. These charges were offset by $30,000 of income from the sale of assets in our Woodland California facility. Net restructuring charges will result in cash outflows and as of September 30, 2005, approximately $508,000 has been
disbursed.



6. Subsequent Events



On October 26, 2005,the Company received notice from The Nasdaq
Stock Market informing the Company that it does not comply with Market Place Rule 4310(c)(B)(ii), which requires the Company to maintain a market value of listed securities of $35,000,000. In accordance with Marketplace Rule 4310(c)(8)(C), the
Company has 30 calendar days, or until November 25, 2005, to regain compliance with the Rule. In the event the Company does not regain compliance by November 25, 2005, the Company shall have the right to appeal a staff determination to delist the
Companys securities and the Companys securities will remain listed until completion of the appeal process.



On November 7, 2005, the Company and sanofi pasteur entered into a termination agreement, terminating the parties strategic partnership.
Specifically, the termination agreement terminated the Companys Co-Promotion Agreement and the License and Supply Agreements with sanofi pasteur relating to the development, manufacture and commercialization of Insegia, the Companys most
advanced cancer immunotherapy. In accordance with the terms of the termination agreement, all of the rights to Insegia granted to sanofi pasteur under the Co-Promotion Agreement and License, including the right to commercialize Insegia in North
America and Europe, revert back to the Company. In exchange for the return of such rights, the Company agreed to pay to sanofi pasteur a nominal single digit royalty on all future worldwide net sales of Insegia and sanofi pasteur forgave a $1.9
million receivable due and owing by the Company. In connection with the dissolution of the Companys strategic partnership with sanofi pasteur, the Company had previously redeemed the Series A Convertible Debenture issued to sanofi pasteur in
2002 in accordance with its terms.



Pursuant to terms of the
termination agreement, sanofi pasteur has agreed to make reasonable commercial efforts to sell to the Company reasonable quantities of diphtheria toxoid (DT), a key ingredient of Insegia, through the year 2009. The initial contract price for the DT
supplied by sanofi pasteur will be subject to an annual adjustment for any increases in the Industrial Price Index. The supply of the DT will be conditioned upon the Company providing 18 month forecasts to sanofi pasteur of the Companys future
DT requirements. The Company and sanofi pasteur agreed to negotiate a new definitive supply agreement that will set forth all of the terms of the supply arrangement.



On November 9, 2005, the Company entered into a binding Letter Agreement with the holders of the 2003 Senior
Convertible Notes (the Holders). Under the terms of the Letter Agreement, the Holders agreed to surrender the 2003 Senior Convertible Notes for cancellation by the Company in exchange for (i) $3,000,000 in cash, (ii) shares of
the Companys 0% Non-participating Series A-1 Convertible Preferred Stock (the Series A Preferred Stock) with an original Stated Value of $10,000,000, and (iii) 6,500,000 shares of the Companys common stock, of which
1,500,000 shares would be delivered into escrow by the Company at closing (the Transaction). The Transaction closed on November 23, 2005.



The shares of Series A Preferred Stock are convertible into shares of the Companys common stock at a price per share of $0.50 (the Series A
Conversion Price), subject to certain antidilution adjustments for a period of up to three years. In no event will the Series A Conversion Price be reduced below $0.48 (the Conversion Price Floor) as a result of an antidilution
adjustment; provided that the Company may not close any offering of its securities without the consent of two-thirds (2/3) of Holders of the then outstanding shares of Series A Preferred Stock, if the result of such offering would have the
effect of reducing the Series A Conversion Price below the Conversion Price Floor.



Subject to certain limitations, the Holders shall be entitled to vote with the holders of the Companys common stock, voting together as one class, on all matters submitted to a vote of the holders of common
stock, and each share of Series A Preferred Stock shall be entitled to a number of votes equal to the number of shares of common stock into which each such share is convertible as of the record date for the applicable vote. The voting rights of the
Holders shall be subject to the following limitation: in the case of each of SF Capital Partners Ltd., Heartland Value Fund and Horizon & Waves Co., the number of votes that such Holder shall be entitled to cast with respect to shares of voting
stock then held by such Holder shall in no event exceed the number of votes that each Holder would be permitted to vote if the Conversion Price Floor was the closing bid price of the common stock as of the date the Series A Preferred Stock is first
issued. The Series A Preferred Stock will have a 0% dividend rate, and shall only receive dividends paid on the Companys common stock on an as-if converted basis and solely as and when declared by the Companys Board of Directors. In the
event of any liquidation or winding up of the Company, including certain acquisitions of the Companys capital stock or assets, the holders of the Series A Preferred Stock will be entitled to a preference payment in an amount equal to the
Stated Value of the then outstanding Series A Preferred Stock (plus all declared but unpaid dividends) in the form of consideration received by the Company or its stockholders, as the case may be.



The Company is obligated to file a registration statement registering the
resale of the shares of the Companys common stock issued and issuable in the Transaction and have the registration statement declared effective within ninety (90) days after the closing of the Transaction, or within 120 days after the
closing of the Transaction if the registration statement is subject to a review by the Securities and Exchange Commission, or become subject to payment of a certain monetary damages. The 1,500,000 shares of common stock delivered into escrow at
closing will remain in escrow for a period of up to two (2) years and subject to return to the Company in the event the Companys common stock trades for a certain period of time at or above $3.23 per share.



9



---

##### Table of Contents

As part of the further development of IGN311, on July 25, 2005, the Company announced that it had
entered into a licensing and commercialization agreement and a product development agreement with Celltrion, Inc. for IGN311, the terms of which were subject to finalizing a supply agreement and quality agreement between the Company and Celltrion.
On November 7, 2005, the Company and Celltrion finalized and executed the supply agreement and quality agreement. Accordingly, the strategic relationship between the Company and Celltrion was consummated on that date. We believe that this
strategic relationship validates the interest in IGN311 and will allow us to expedite the development of IGN311 in a cost-efficient manner.



10



---

##### Table of Contents

|Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations
|------- | -------------------------------------------------------------------------------------



Overview



General



We are a biopharmaceutical company focused on developing innovative cancer therapies. Our research and development efforts are based on our proprietary active immunization and monoclonal antibody technologies. Our
technologies are based on key discoveries made by us as well as our understanding of the central role of gastrin, a naturally occurring hormone, and gastrin receptors. Through our wholly-owned subsidiary, Igeneon, we are focused on the development
of active and passive cancer immunotherapies (cancer vaccines and monoclonal antibodies) designed to prevent or delay the development of metastases in cancers of epithelial origin. These product candidates are designed to target disseminated tumor
cells, thereby having the potential to prevent metastasis and the spread of cancer.



One of our lead product candidates, which we acquired through our acquisition of Igeneon in March 2005, is IGN101, a cancer vaccine which is currently in a Phase II/III randomized double blind clinical trial in
non-small cell lung cancer patients. We recently reached target accrual of 760 patients in this study, three months ahead of schedule. We expect to have final data available from this study in 2007. In addition, on May 16, 2005, we announced
that results from our double-blind, placebo-controlled Phase II clinical trial of IGN101 in patients with solid tumors were presented at the 2005 Annual Meeting of the American Society for Clinical Oncology (ASCO). In the study, a statistically
significant difference in overall survival was seen in a subgroup of patients with rectal cancer and a positive trend toward survival improvement was observed in patients with colon cancer. This trial was conducted in 240 patients with epithelial
cancers, which consists of colorectal cancer, gastrointestinal tract cancer, non-small cell lung cancer and liver cancer.



Another product-candidate we acquired through our acquisition of Igeneon is IGN311, a monoclonal antibody targeting Lewis Y-positive cancer cells. We
recently completed an open-label dose escalating Phase I trial with IGN311 and on July 12, 2005, we announced the positive results from this study. In the Phase I trial, IGN311 demonstrated favorable safety and tolerability, and advantageous
pharmacokinetics with a serum half-life of more than 20 days. Data from the trial also indicate efficacy of IGN311 against Lewis Y-positive tumor cells circulating in peripheral blood. As a result of this positive data, we have moved forward with a
Phase I/II clinical trial with IGN311 and on July 21, 2005, we announced that initiation of the open-label Phase I/II began with the enrollment of our first patient. As part of the further development of IGN311, on July 25, 2005, we
announced that we had entered into a licensing and commercialization agreement and a product development agreement with Celltrion, Inc. for IGN311, the terms of which were subject to the parties finalizing a supply agreement and quality agreement.
On November 7, 2005, the supply agreement and quality agreement were finalized and the strategic relationship between us and Celltrion was consummated. We believe that this strategic relationship validates the interest in IGN311 and will allow
us to expedite the development of IGN311 in a cost-efficient manner.



Our most advanced product-candidate is Insegia (G17DT immunogen). We have completed two Phase III clinical trials for the treatment of pancreatic cancer with Insegia. We also completed testing of Insegia in one Phase II clinical trial for
the treatment of gastric cancer and one Phase II clinical trial for the treatment of colorectal cancer. On May 11, 2005, we announced that as a result of a cost-reduction program we no longer had the internal resources to allocate toward the
clinical development of Insegia. However, we have been encouraged by the results achieved in patients who achieved an antibody response in clinical trials with Insegia as both a monotherapy, and in combination with chemotherapy.



On November 7, 2005, we entered into a termination agreement with sanofi
pasteur, terminating the parties strategic alliance. Specifically, the termination agreement terminated the Co-Promotion Agreement and the License and Supply Agreements with sanofi pasteur relating to the development, manufacture and
commercialization of Insegia, the Companys most advanced cancer immunotherapy. In accordance with the terms of the termination agreement, all of the rights to Insegia granted to sanofi pasteur under the Co-Promotion Agreement and License,
including the right to commercialize Insegia in North America and Europe, revert back to us. In exchange for the return of such rights, we agreed to pay to sanofi pasteur a nominal single digit royalty on all future worldwide net sales of Insegia
and sanofi pasteur forgave a $1.9 million receivable due and owing by us. In connection with the dissolution of the Companys strategic partnership with sanofi pasteur, we had previously redeemed the original principal amount of our outstanding
Series A Convertible Debenture issued to sanofi pasteur in 2002. Accordingly, we are currently devoting significant effort to seeking partners that have the financial resources to support additional clinical studies and/or other research and
development activities that may be necessary to support regulatory approval of Insegia for patients with gastrin-sensitive cancers. We believe that the activity demonstrated by Insegia in patients with gastrin-sensitive cancers should enhance our
ability to find an appropriate partner to assist in developing Insegia. In addition, we believe that now having the ability to license Insegia on a worldwide basis, because of the termination of our relationship with sanofi pasteur, will greatly
enhance our ability to find a partner financially capable of and committed to further developing Insegia.



11



---

##### Table of Contents

Financial Operations



We do not have any products approved for sale in the United States or abroad. Therefore, we do not generate any revenue from the sale of our products. We
have experienced significant operating losses since our inception in 1981 and expect to continue incurring significant operating losses for at least the next several years. We expect losses to continue over the next several years as we continue our
clinical trials, apply for regulatory approvals and continue our research and development efforts. We also expect to experience negative operating cash flows for the foreseeable future. Our losses have adversely impacted, and will continue to
adversely impact, our working capital, total assets and stockholders equity (deficit).



Our net loss for the nine months ended September 30, 2005, was $62.1 million including non-cash charges of $35.7 million. As of September 30, 2005, we had an accumulated deficit of approximately $257.8
million. Our operating losses are primarily due to the costs of development of our product-candidates and employee salaries. These costs can vary significantly from year to year depending on the number of product-candidates in development, the stage
of development of each product-candidate, the number of patients enrolled, complexity of clinical trials and other factors, and the number of employees needed to operate our business. Our ability to achieve profitability depends upon our ability,
alone or through relationships with third parties, to develop successfully our technology and product-candidates, to obtain required regulatory approvals and to manufacture, market and sell such product-candidates. It is possible that we may never
be profitable.



We do not currently have any source of
operating revenue and will require significant amounts of cash to continue to fund our operations, our clinical trials and our research and development efforts until such time, if ever, that one of our products has received regulatory approval for
marketing. Because we have not generated any revenue from the sale of any products, we have primarily relied on the capital markets as our source of funding. Results of our recent Insegia clinical trial and other factors have weakened the market
value of the Companys common stock and made it difficult for us to access the capital markets to obtain financing on terms that would benefit us in the long term. However, because we have recently entered into an agreement with the holders of
the Companys Senior Convertible Notes to exchange the notes for a combination of cash, preferred stock and common stock, we will continue to be opportunistic in accessing the capital markets to obtain financing on terms satisfactory to us. In
addition, we continue to explore a number of alternatives, including licensing or selling a significant portion or all of our intellectual property and/or other assets, the sale or exchange of a significant portion or all of our equity, or pursuing
other financing alternatives. We may implement one or more of these alternatives. If we are successful in obtaining any financing, we intend to use the net proceeds we receive from the financing to fund our operations and support the clinical
development of our product candidates. No assurances, however, can be given that we will close the exchange transaction for the Senior Convertible Notes, consummate a capital raise on terms satisfactory to us or that any particular strategic
transaction will be completed, nor can any prediction or assurance be made regarding the possible impact of future transactions on our business, results or capitalization. Our ability to consummate the exchange of the 2003 Senior Convertible Notes,
our ability to make interest or principal payments on our indebtedness, comply with the covenants in our indebtedness documents, or effectively implement any of the above-mentioned alternatives to fund our future operations is dependent on many
factors, many of which are beyond our control.



Cost-Reduction Program



In connection with the Igeneon acquisition and after
further analysis of the results our Phase III clinic trial of Insegia, we began a review of all of our consolidated resources, budgeted expenditures and the clinical trials and research and development efforts being conducted by the two companies.
As a result of such review, in May 2005, we began implementing a cost-reduction program intended to align our expenses with product development priorities with the goal of improving our operating efficiencies. Based on the current value of our stock
price, we believe that our ability to raise substantial amounts of capital to fund our combined operations is limited and therefore we need to identify and fund those programs which we believe provide the most potential return to stockholders.
Accordingly, we began the process of closing our Woodland, California facility, and decommissioning our research and development and Quality Assurance/Quality Control programs located there.



We currently anticipate that the entire decommissioning process of the
Woodland facility and operations should be complete by November 30, 2005. The responsibilities for most of the positions eliminated at Woodland will be transferred to our corporate office in Philadelphia and our other research and development
facilities located in Austria and the United Kingdom. During the quarter ended September 30, 2005, we recognized $30,000 in restructuring income associated with the sale of assets from our Woodland facility. We do not believe that the
elimination of the positions and the closing of the Woodland facility will adversely affect our ability to pursue the humanization and development of a gastrin monoclonal antibody or the development of IGN101 or IGN311, or hinder our ability to find
a strategic partner to assist us in the further development of Insegia.



We continue to monitor our current cash position and believe that in the event we are unable to obtain financing either through the capital markets or by entry into a strategic alliance, we will need to reduce our current cash burn further
through the elimination of employee positions and the termination of certain projects.



Critical Accounting Policies



The preparation
of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets
and



12



---

##### Table of Contents

liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could
differ from those estimates, however, we believe such differences are unlikely to be significant.



Our significant accounting policies are described in Note 1 to the financial statements included in this Quarterly Report. We believe that our most
critical accounting policies include the use of estimates. The impact of these estimates on results of operations for the three and nine months ended September 30, 2005 and 2004, respectively, were not significant. We periodically review these
policies and estimates, the effect of which is reflected as a component of net loss in the period in which the change is known.



Convertible Debt Issued with Stock Purchase Warrants



We account for convertible debt issued with stock purchase warrants in accordance with Accounting Principles Board Opinion No. 14, Accounting for
Convertible Debt and Debt Issued with Stock Purchase Warrants, Emerging Issues Task Force (EITF) No. 98-5, Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios, and
EITF No. 00-27, Application of Issue No. 98-5 to Certain Convertible Instruments.



Income taxes



We
account for income taxes pursuant to Statement of Financial Accounting Standards (SFAS) No. 109, Accounting for Income Taxes, which requires an asset and liability approach in accounting for income taxes. Under this method, the
amount of deferred tax asset or liability is calculated by applying the provisions of enacted tax laws to the differences in the bases of assets and liabilities for financial and income tax purposes. For all periods presented the deferred tax assets
are fully reserved.



Research and Development Expenses



Research and development costs are expensed as incurred. These costs include
external and internal research and development costs, the salaries of dedicated personnel, the allocated salaries of personnel who also perform general and administrative tasks, the costs of the dedicated research and development facilities and the
costs of contracted researchers. There is no allocation of administrative expense or corporate costs to research and development costs.



Foreign Currency Accounting



The Company complies withSFAS No. 52 Foreign Currency Translation,which established standards for reporting on foreign
subsidiaries in consolidated financial statements.



13



---

##### Table of Contents

Results of Operations



Three months ended September 30, 2005 and 2004



|                                              |  |                                 |        |   |                          |   |        |   |  |      |  
|--------------------------------------------- |  | ------------------------------- | ------ | - | ------------------------ | - | ------ | - |  | ---- | -
|                                              |  | Three months EndedSeptember 30, |        |   | % Changefrom2004 to 2005 |  
|                                              |  | 2005                            |        |   | 2004                     |   |       
|                                              |  | (in thousands)                  |       
|Revenue:                                      |  | $                               |       |   |                          | $ |       |   |  |     |  
|Costs and expenses:                           |  |                                 |        |   |                          |   |        |   |  |      |  
|General and administrative                    |  |                                 | 3,146  |   |                          |   | 935    |   |  | 236  | %
|Research and development                      |  |                                 | 4,582  |   |                          |   | 5,814  |   |  | -21  | %
|Acquired in-process research and development  |  |                                 |       |   |                          |   |       |   |  |     |  
|Restructuring expense                         |  |                                 | 288    |   |                          |   |       |   |  |     |  
|                                              |  |                                 |        |   |                          |   |        |   |  |      |  
|Total costs and expenses                      |  |                                 | 8,016  |   |                          |   | 6,749  |   |  | 19   | %
|                                              |  |                                 |        |   |                          |   |        |   |  |      |  
|Loss from operations                          |  |                                 | (8,016 | ) |                          |   | (6,749 | ) |  | 19   | %
|                                              |  |                                 |        |   |                          |   |        |   |  |      |  
|Other income (expense):                       |  |                                 |        |   |                          |   |        |   |  |      |  
|Dividend and interest income                  |  |                                 | 93     |   |                          |   | 224    |   |  | -58  | %
|Interest expense including amortized discount |  |                                 | (831   | ) |                          |   | (677   | ) |  | 23   | %
|Unrealized gain from investments              |  |                                 | 23     |   |                          |   | (31    | ) |  | -176 | %
|                                              |  |                                 |        |   |                          |   |        |   |  |      |  
|Net loss                                      |  |                                 | (8,731 | ) |                          |   | (7,233 | ) |  | 21   | %
|                                              |  |                                 |        |   |                          |   |        |   |  |      |  



General and
administrative expenses. General and administrative expenses are primarily comprised of expenses related to intellectual property, general corporate and patent legal costs and the salaries of our administrative personnel. The increase in our
general and administrative expenses for the three months ended September 30, 2005, compared to the three months ended September 30, 2004, was primarily due to the inclusion of the general and administrative costs associated with our
wholly-owned subsidiary, Igeneon, for the full three months ended September 30, 2005, and an increase in salary and benefits of our administrative personnel.



Research and development expenses. Research and development expenses are primarily comprised of the external costs of
contracted clinical research organizations, or CROs, and, to a lesser extent, our external and internal research and development costs which include the salaries of dedicated and allocated personnel and the costs of the dedicated and allocated
research and development facilities. The decrease in our research and development expenses for the three months ended September 30, 2005, compared to the three months ended September 30, 2004, was primarily due to the continued
implementation of our cost-reduction program and the completion of certain of our clinical trials.



Restructuring expenses.On May 11, 2005, the Company began implementing a cost-reduction program intended to align expenses with product
development priorities. As of September 30, 2005, 27 employees had been terminated. The restructuring charge taken at September 30, 2005, was $1,106,000. Included in this amount is $1,085,000 for severance and other professional services
of $51,000. These charges were offset by $30,000 of income from the sale of assets in our Woodland California facility. Net restructuring charges will result in cash outflows and as of September 30, 2005, approximately $508,000 has been
disbursed.



Net loss. The increase in net loss for the
three months ended September 30, 2005, compared to the three months ended September 30, 2004, was primarily due to the inclusion of the general and administrative costs and research and development costs associated with our wholly-owned
subsidiary, Igeneon, for the three months ended September 30, 2005.



Interest expense including amortized discount. Interest expense including amortized discount of $382,400 was $831,000 for the three months ended September 30, 2005, compared with interest expense including
amortized discount of $294,180 of $677,457 for the three months ended September 30, 2004. This increase is due primarily to the increase of the amortized discount of our convertible debt instruments and the assumption of interest payment
obligations associated with Igeneons outstanding debt.



14



---

##### Table of Contents

Nine months ended September 30, 2005 and 2004



|                                              |  |                                |         |   |                          |   |         |   |  |      |  
|--------------------------------------------- |  | ------------------------------ | ------- | - | ------------------------ | - | ------- | - |  | ---- | -
|                                              |  | Nine months EndedSeptember 30, |         |   | % Changefrom2004 to 2005 |  
|                                              |  | 2005                           |         |   | 2004                     |   |        
|                                              |  | (in thousands)                 |        
|Revenue:                                      |  | $                              |        |   |                          | $ |        |   |  |     |  
|Costs and expenses:                           |  |                                |         |   |                          |   |         |   |  |      |  
|General and administrative                    |  |                                | 8,500   |   |                          |   | 2,597   |   |  | 227  | %
|Research and development                      |  |                                | 17,730  |   |                          |   | 15,978  |   |  | 11   | %
|Acquired in-process research and development  |  |                                | 32,992  |   |                          |   |        |   |  |     |  
|Restructuring expense                         |  |                                | 1,106   |   |                          |   |        |   |  |     |  
|                                              |  |                                |         |   |                          |   |         |   |  |      |  
|Total costs and expenses                      |  |                                | 60,328  |   |                          |   | 18,575  |   |  | 225  | %
|                                              |  |                                |         |   |                          |   |         |   |  |      |  
|Loss from operations                          |  |                                | (60,328 | ) |                          |   | (18,575 | ) |  | 225  | %
|                                              |  |                                |         |   |                          |   |         |   |  |      |  
|Other income (expense):                       |  |                                |         |   |                          |   |         |   |  |      |  
|Dividend and interest income                  |  |                                | 636     |   |                          |   | 368     |   |  | 73   | %
|Interest expense including amortized discount |  |                                | (2,424  | ) |                          |   | (1,977  | ) |  | 23   | %
|Unrealized gain from investments              |  |                                |        |   |                          |   | (20     | ) |  | -100 | %
|                                              |  |                                |         |   |                          |   |         |   |  |      |  
|Net loss                                      |  |                                | (62,116 | ) |                          |   | (20,204 | ) |  | 207  | %
|                                              |  |                                |         |   |                          |   |         |   |  |      |  



General and
administrative expenses. General and administrative expenses are primarily comprised of expenses related to intellectual property, general corporate and patent legal costs and the salaries of our administrative personnel. The increase in our
general and administrative expenses for the nine months ended September 30, 2005, compared to the nine months ended September 30, 2004, was primarily due to the inclusion of the general and administrative costs associated with our
wholly-owned subsidiary, Igeneon, for the full nine months ended September 30, 2005, an increase in salary and benefits of our administrative personnel, and costs associated with our acquisition of Igeneon.



Research and development expenses. Research and development expenses
are primarily comprised of the external costs of contracted clinical research organizations, or CROs, and, to a lesser extent, our external and internal research and development costs which include the salaries of dedicated and allocated personnel
and the costs of the dedicated and allocated research and development facilities. The increase in our research and development expenses for the nine months ended September 30, 2005, compared to the nine months ended September 30, 2004, was
primarily due to an increase in expenses associated with the research and development of our newly acquired product-candidates, IGN101 and IGN311, and certain other programs of Igeneon. This increase was offset partially by the implementation of our
cost-reduction program and the completion of certain of our clinical trials.



Acquired in-process research and development expenses.The acquired in-process research and development costs were expensed in conjunction with the acquisition of Igeneon as it was determined that the
development of these projects had not yet reached technological feasibility.



Restructuring expenses. On May 11, 2005, we began implementing a cost-reduction program intended to align expenses with product development priorities. As of September 30, 2005, 27 employees have been
terminated. The restructuring charge taken at September 30, 2005 was $1,106,000. Included in this amount is $1,085,000 for severance and other professional services of $51,000. These charges were offset by $30,000 of income from the sale of
assets at our Woodland California facility. Net restructuring charges will result in cash outflows and as of September 30, 2005, approximately $508,000 has been disbursed.



Interest expense including amortized discount. Interest expense including amortized discount of $1.1 million was $2.4
million for the nine months ended September 30, 2005, compared with interest expense including amortized discount of $830,000 was $2.4 million for the nine months ended September 30, 2004. This increase is due primarily to the increase of
the amortized discount of our convertible debt instruments and the assumption of interest payment obligations associated with Igeneons outstanding debt.



Net loss. The increase in net loss for the nine months ended September 30, 2005, compared to the nine months ended September 30, 2004,
was primarily due to the inclusion of the general and administrative costs and research and development costs associated with our wholly-owned subsidiary, Igeneon, for the full nine months ended September 30, 2005, and costs associated with our
acquisition of Igeneon.



15



---

##### Table of Contents

Liquidity and Capital Resources



We finance our operations through the sale of our equity and convertible securities and the exercise of outstanding
warrants. We also seek to finance our operations by entering into arrangements with strategic partners, whereby we would license certain of our product-candidates in exchange for licensing fees.



We do not currently have any source of operating revenue and will require
significant amounts of cash to continue to fund our operations, our clinical trials and our research and development efforts until such time, if ever, that one of our products has received regulatory approval for marketing. Because we have not
generated any revenue from the sale of any products, we have primarily relied on the capital markets as our source of funding. Results of our recent Insegia clinical trial and other factors have weakened the market value of the Companys common
stock and made it difficult for us to access the capital markets to obtain financing on terms that would benefit us in the long term. However, because we have recently entered into an agreement with the holders of the Companys Senior
Convertible Notes to exchange the notes for a combination of cash, preferred stock and common stock, we will continue to be opportunistic in accessing the capital markets to obtain financing on terms satisfactory to us. In addition, we continue to
explore a number of alternatives, including licensing or selling a significant portion or all of our intellectual property and/or other assets, the sale or exchange of a significant portion or all of our equity, or pursuing other financing
alternatives. We may implement one or more of these alternatives. If we are successful in obtaining any financing, we intend to use the net proceeds we receive from the financing to fund our operations and support the clinical development of our
product candidates. No assurances, however, can be given that we will close the exchange transaction for the Senior Convertible Notes, consummate a capital raise on terms satisfactory to us or that any particular strategic transaction will be
completed, nor can any prediction or assurance be made regarding the possible impact of future transactions on our business, results or capitalization. Our ability to consummate the exchange of the 2003 Senior Convertible Notes, our ability to make
interest or principal payments on our indebtedness, comply with the covenants in our indebtedness documents, or effectively implement any of the above-mentioned alternatives to fund our future operations is dependent on many factors, many of which
are beyond our control.



As of September 30, 2005, we had
cash and short-term cash equivalents totaling $14.8 million and working capital of $(6.4) million compared to cash and short-term cash equivalents totaling $43.4 million and a working capital of $34.3 million at December 31, 2004. The decrease
in working capital was primarily due to a reclassification from a non-current liability to a current liability for $9.9 million of the Companys convertible debt and the use of cash to repay indebtedness and support operations.



Indebtedness



During the three months ended September 30, 2005, our aggregate principal amount of convertible debentures and notes
outstanding was reduced from $23.0 million at June 30, 2005 to $20.0 million at September 30, 2005. This reduction was due to the redemption of the $3.0 million of our Series A Convertible Debenture (the Series A Convertible Debenture),
in accordance with its terms. The Series A Convertible Debenture was a convertible, redeemable, five-year debenture that was to mature on December 19, 2007. At any time prior to maturity, we had the right to redeem the Series A Convertible
Debenture. In addition, at any time prior to maturity, we had the obligation to redeem the Series A Convertible Debenture under certain conditions, including if we transferred our rights to certain projects or other products, or any other rights
related thereto, to any entity, other than the holder of the Series A Convertible Debenture or its affiliates. The Series A Convertible Debenture bore interest at a rate of 11.0% per annum, payable annually and was convertible, at the holders
option, at a conversion price equal to the average closing price of our common stock, as defined in the Series A Convertible Debenture, at the time of conversion. In connection with the dissolution of our strategic partnership with sanofi pasteur,
we redeemed the Series A Convertible Debenture in August 2005.



As of September 30, 2005, we had an aggregate principal amount outstanding of $20.0 million of 2003 Senior Convertible Notes. There was an initial discount calculated against the value of the 2003 Senior Convertible Notes of $12.9
million, comprised of the beneficial conversion feature of $8.3 million and other discounts attributable to the value of the detachable warrants issued in conjunction with the 2003 Senior Convertible Notes of $4.6 million.



The 2003 Senior Convertible Notes are redeemable five-year interest-bearing
notes which we issued in two tranches to accredited investors in 2003. On April 4, 2003, we issued $15.0 million of our 2003 Senior Convertible Notes and 5-year warrants to purchase an aggregate total of 1,080,000 shares of our common stock to
various accredited investors. On June 12, 2003, we issued an additional $5.0 million of our 2003 Senior Convertible Notes and a 5-year warrant to purchase an aggregate total of 360,000 shares of our common stock to an accredited investor. The
2003 Senior Convertible Notes mature on March 31, 2008. We have the right and obligation to redeem the 2003 Senior Convertible Notes under certain conditions at any time after the third year from the issuance date. The 2003 Senior Convertible
Notes bear interest at a rate of 6.0% per annum, payable quarterly in cash or shares of our common stock, at our option.



On November 9, 2005, we entered into a binding Letter Agreement with the holders of the 2003 Senior Convertible Notes (the Holders).
Under the terms of the Letter Agreement, the Holders agreed to surrender the 2003 Senior Convertible Notes for cancellation by us in exchange for (i) $3,000,000 in cash, (ii) shares of our 0% Non-participating Series A-1 Convertible
Preferred Stock (the Series A Preferred Stock) with an original Stated Value of $10,000,000, and (iii) 6,500,000 shares of our common stock, of which 1,500,000 shares would be subject to an escrow. The transaction closed on November
23, 2005.



The Series A Preferred Stock has a 0% dividend rate,
and shall only receive dividends paid on our common stock on an as-if converted basis and solely as and when declared by our Board of Directors. In the event of any liquidation or winding up, including certain acquisitions of our capital stock or
assets, the holders of the Series A Preferred Stock will be entitled to a preference payment in an amount equal to the Stated Value of the then outstanding Series A Preferred Stock (plus all declared but unpaid dividends in the form of consideration
received by the Company or its stockholders, as the case may be).



16



---

##### Table of Contents

As of September 30, 2005, our wholly-owned subsidiary, Igeneon, had $6.9 million in USD equivalents
in interest-bearing liabilities as compared to $7.5 million in USD at June 30, 2005. These liabilities are comprised of financial liabilities relating to funds received by Igeneon prior to the acquisition from various financial institutions and
guaranteed by governmental agencies for Igeneons research and development activities. The table below provides the amounts outstanding (in thousands in USD Equivalents), the maturity of each liability and the interest rate.



|                                                          |  |             |       |          |                |               |                  |  
|--------------------------------------------------------- |  | ----------- | ----- | -------- | -------------- | ------------- | ---------------- | -
|Institution                                               |  | Outstanding |       | Maturity |                | Interest rate |                 
|Österreichische Forschungsförderungs-gesellschaft (EUR)   |  | $           | 562   |          | June 30, 2006  |               | 3.0              | %
|Bank Austria Creditanstalt (ERP-Investitionskredit) (EUR) |  | $           | 2,714 |          | July 1, 2006   |               | 0.5              | %
|Bank Austria Creditanstalt (FFG-Investitionskredit) (EUR) |  | $           | 883   |          | June 30, 2007  |               | 3-m.EURIBOR +0.6 | %
|Erste Bank (FFG-Kredit) (EUR)                             |  | $           | 482   |          | March 31, 2008 |               | 3-m.EURIBOR +0.6 | %
|Bank Austria Creditanstalt (FFG-Kredit) (EUR)             |  | $           | 1,061 |          | June 30, 2009  |               | 3-m.EURIBOR +0.5 | %
|Erste Bank (AWS-Kredit) (EUR)                             |  | $           | 1,205 |          | July 1, 2010   |               | 3-m.EURIBOR +0.5 | %
|                                                          |  |             |       |          |                |               |                  |  
|Total                                                     |  | $           | 6,907 |          |                |               |                  |  
|                                                          |  |             |       |          |                |               |                  |  



Uses of Funds



The primary uses of our cash are to fund our operations and working capital
requirements, specifically, to fund our research and development activities and our pre-clinical and clinical studies for our product candidates. Our uses of cash for operating activities and capital expenditures during the nine months ended
September 30, 2005 and 2004, were as follows:



|                                      |  |                                 |        |      |   |       
|------------------------------------- |  | ------------------------------- | ------ | ---- | - | ------
|                                      |  | Nine months ended September 30,
|                                      |  | 2005                            |        | 2004
|                                      |  | (in thousands)                 
|Net cash used in operating activities |  | $                               | 25,082 |      | $ | 18,261
|Capital expenditures                  |  |                                 | 115    |      |   | 293   
|                                      |  |                                 |        |      |   |       
|Total                                 |  | $                               | 25,197 |      | $ | 18,554
|                                      |  |                                 |        |      |   |       



The net cash used in
operating activities is comprised of our net losses and working capital requirements.



Liquidity



Based on our current operating
plans, including the successful implementation of our cost reduction plan discussed above, the consummation of the exchange of our 2003 Senior Convertible Notes and the completion of a successful fund raise, and our current estimates of contractual
obligations, we believe that our existing capital resources, which consist primarily of cash and short-term cash investments, together with the funds raised if we complete a successful offering of our securities, will enable us to maintain
operations through 2006. However, there can be no assurance that we will consummate an offering of our securities or the exchange of our 2003 Senior Convertible Notes or that changes in our research and development plans or other future events
affecting our operating expenses will not result in the depletion of our funds at an earlier time.



Our working capital and capital requirements will depend upon numerous factors, including the following: the progress of our research and development
program; pre-clinical testing and clinical trials; the timing and cost of obtaining regulatory approvals; the levels of resources that we devote to product development, manufacturing and marketing capabilities; technological advances; competition;
and collaborative arrangements or strategic alliances with other drug companies, including the further development, manufacturing and marketing of certain of our products and our ability to obtain funds from such strategic alliances or from other
sources and any repayments that we may be make on our outstanding indebtedness. Many of these factors are beyond our control. As discussed above, in addition to an offering of our securities and the exchange of our 2003 Senior Convertible Notes, we
continue to explore a number of strategic and other financing alternatives, including licensing or selling a significant portion or all of our intellectual property and/or other assets, the sale or exchange of a significant portion or all of our
equity, or pursuing other financial alternatives. Even if we are successful in completing an offering of our securities and/or the exchange of our notes, we may implement one or more of these alternatives. If we are unable to complete such
transactions, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs and/or implement further reductions in our workforce. We cannot assure you that any of these alternatives can be
consummated, or if consummated, would effectively address the risks associated with our negative cash flow.



17



---

##### Table of Contents

Special Note Regarding Forward-Looking Statements



This quarterly report contains forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.



These statements concern expectations, beliefs, intentions, projections, future plans and strategies, anticipated events or trends and similar expressions
concerning matters that are not historical facts. Specifically, this quarterly report contains forward-looking statements regarding:



| |  |  | our intention to continue to be opportunistic in accessing the capital markets to obtain financing on terms satisfactory to us;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------



| |  |  | our expectations regarding losses and negative operating cash flows for the next several years and the impact on working capital, total assets and stockholders equity;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our expectations as to the adequacy of existing capital resources to support our operations and periodic interest obligations, if any, into 2006;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our belief that the impact of our use of estimates is not significant on our results of operations;
| | - |  | ---------------------------------------------------------------------------------------------------



| |  |  | our current expectation that the operations of Igeneon will generate sufficient funds someday in the future to repay its liabilities;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to implement our cost-reduction plan, including decommissioning Woodland, to align our expenses with our product development priorities and improve our operating
efficiencies and to allocate adequate resources to projects that we believe offer us the best opportunity to create value for shareholders;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our belief that reprioritization of research resources will not adversely affect our ability to pursue the humanization and development of a gastrin monoclonal antibody and the
development of IGN101 and IGN311 product-candidates, or hinder our ability to find a strategic partner to assist us in the further development of Insegia;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our belief that our strategic alliance with Celltrion validates the interest in IGN311, will result in a cost savings to us of $10 million and will allow us to expedite the
development of IGN311 in a cost-efficient manner;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability and our expectation that we will successfully negotiate a supply agreement with sanofi pasteur or any other party;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------



| |  |  | our current intent to explore a number of alternatives, including licensing or selling a significant portion or all of our intellectual property and/or other assets, the sale or
exchange of a significant portion or all of our equity, or pursuing other financial alternatives and our belief that one or more of these alternatives may address the risks associated with our negative cash flow;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our belief that if we are unable to obtain sufficient financing, either through the capital markets or by entry into a strategic alliance, we will need to reduce our current cash
burn further through the elimination of employee positions and termination of certain projects;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our intent to continue to seek partners that have the financial resources to support additional clinical studies and/or other research and development to support regulatory approval
of Insegia for use in patients with gastrin-sensitive cancers and our belief that the activity demonstrated by Insegia in patients with gastrin-sensitive cancers and the dissolution of our strategic alliance with sanofi pasteur should enhance our
ability to find an appropriate partner for Insegia;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our expectations that final data from the current Phase II/III study of IGN101 will be available in 2007; and
| | - |  | -------------------------------------------------------------------------------------------------------------



| |  |  | our expectations that we will implement the remediation steps necessary to make our disclosure controls and procedures effective and to address the significant deficiencies and/or
material weakness in our internal control over financial reporting by the end of the year.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We caution
investors that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. The most important factors
that could prevent us from achieving our goals, and cause the assumptions underlying forward-looking statements and the actual results to differ materially from those expressed in or implied by those forward-looking statements include, but are not
limited to, the following:



| |  |  | our ability to obtain additional financing or reduce our costs and expenses;
| | - |  | ----------------------------------------------------------------------------



| |  |  | our ability to identify and realize anticipated cost efficiencies;
| | - |  | ------------------------------------------------------------------



18



---

##### Table of Contents

| |  |  | our ability to develop, obtain regulatory approval for, produce in commercial quantities and gain commercial acceptance for our product candidates;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to maintain and enter into new arrangements and collaborations with third parties, including sanofi pasteur, for the supply of key materials and/or assistance in the
manufacture, market, sale and distribution of our products;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to attract and retain highly qualified scientists and other technical personnel;
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | our ability to fund the further development of our research and development programs and effectively prioritize our research and development programs to allocate adequate resources
to projects;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to consummate a strategic or financial transaction that would support our long-term operations on terms as favorable to us as we would desire, or at all;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to identify a partner willing to fund the continued development of Insegia;
| | - |  | ---------------------------------------------------------------------------------------



| |  |  | scientific developments regarding immunotherapies;
| | - |  | --------------------------------------------------



| |  |  | our ability to protect our patent and other intellectual property rights from infringement by third parties and to ensure that those rights do not become the subject of infringement
claims by third parties;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to successfully integrate Igeneons operations and product portfolio with our operations and product portfolio;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------



| |  |  | the actual design, results and timing of preclinical and clinical studies for our and Igeneons products and product candidates;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to maintain the listing of our common stock on The Nasdaq Stock Market; and
| | - |  | ---------------------------------------------------------------------------------------



| |  |  | our ability to successfully implement the remediation steps necessary to make our disclosure controls and procedures effective and to address the significant deficiencies and/or
material weakness in our internal control over financial reporting by the end of the year.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Item 3. | Quantitative and Qualitative Disclosure about Market Risk
|------- | ---------------------------------------------------------



We do not engage in trading market risk sensitive instruments or purchasing hedging instruments or other than trading instruments that are
likely to expose us to significant market risk, whether interest rate, foreign currency exchange, commodity price or equity price risk.



Foreign Currency Exchange Risk.We have a significant subsidiary with financial liabilities and on-going operations in Austria. In addition, we
have laboratory and staff in England. Consequently, we are exposed to significant currency exchange risk in Euros and Great Britain Pounds. We have, and will continue to have, significant expenses that are denominated in these two currencies. If the
U.S. dollar weakens relative to either of these foreign currencies, any losses generated in the foreign currency will, in effect, increase when converted into U.S. dollars and vice versa. In addition, the financial liabilities of Igeneon are
denominated in Euros; therefore if the U.S. dollar weakens relative to the Euro our amount of financial liabilities will increase when converted into U.S. dollars. We currently expect the operations of Igeneon, which are denominated in Euros, to
generate sufficient funds someday in the future to repay these liabilities.



We do not speculate in the foreign exchange market and currently do not manage exposures that arise in the normal course of business related to fluctuations in foreign currency exchange rates by entering into
offsetting positions through the use of foreign exchange forward contracts. We also do not engage in derivative activities.



Interest Rate Risk. At September 30, 2005, we had cash and current investments in the amount of $14.8 million. We also had principal amount of
convertible debentures and notes payable of $26.9 million. Cash equivalents consist of money market funds and short term investments with maturities of three months or less placed with major financial institutions.



We are exposed to certain market risks that are inherent in our financial
instruments. Specifically, our wholly-owned subsidiary, Igeneon, is subject to interest rate risk on its variable rate financial liabilities. The following table presents the future principal payment obligations and interest rates associated with
Igeneons financial liabilities as of September 30, 2005:



|                                                                         |  |                                 |  |       |  |      |  |      |  |      |  |            |  |       |  |          
|------------------------------------------------------------------------ |  | ------------------------------- |  | ----- |  | ---- |  | ---- |  | ---- |  | ---------- |  | ----- |  | ---------
|                                                                         |  | 2005                            |  | 2006  |  | 2007 |  | 2008 |  | 2009 |  | Thereafter |  | Total |  | FairValue
|                                                                         |  | in thousands in USD equivalents
|Financial Liabilities                                                    |  |                                 |  |       |  |      |  |      |  |      |  |            |  |       |  |          
|Fixed Rate Liabilities                                                   |  |                                 |  |       |  |      |  |      |  |      |  |            |  |       |  |          
|Österreichische Forschungsförderungs-gesellschaft (Avg. Rate 2.5%) (EUR) |  | 0                               |  | 562   |  |     |  |     |  |     |  |           |  | 562   |  | 427      
|Bank Austria Creditanstalt (0.5%) (EUR)                                  |  |                                |  | 2,714 |  |     |  |     |  |     |  |           |  | 2,714 |  | 2,008    
|Variable Rate Liabilities                                                |  |                                 |  |       |  |      |  |      |  |      |  |            |  |       |  |          
|Bank Austria Creditanstalt (Euribor +0.6%) (EUR)                         |  | 221                             |  | 441   |  | 221  |  |     |  |     |  |           |  | 883   |  | 653      
|Bank Austria Creditanstalt (FFG-Kredit) (Euribor +0.5%) (EUR)            |  |                                |  | 227   |  | 314  |  | 314  |  | 156  |  |           |  | 1,061 |  | 647      
|Erste Bank (FFG-Kredit) (Euribor +0.6%) (EUR)                            |  |                                |  | 120   |  | 241  |  | 121  |  |     |  |           |  | 482   |  | 381      
|Erste Bank (AWS-Kredit) (Euribor +0.5%) (EUR)                            |  |                                |  |      |  |     |  | 403  |  | 401  |  | 401        |  | 1,205 |  | 590      



19



---

##### Table of Contents

The following table presents the future principal payment obligations at maturity and interest rates
associated with our direct financial liabilities as of September 30, 2005:



|                                           |  |      |  |      |  |      |  |      |        |      |   |            |   |       |   |           |  |   |      
|------------------------------------------ |  | ---- |  | ---- |  | ---- |  | ---- | ------ | ---- | - | ---------- | - | ----- | - | --------- |  | - | -----
|                                           |  | 2005 |  | 2006 |  | 2007 |  | 2008 |        | 2009 |   | Thereafter |   | Total |   | FairValue
|Convertible Debentures                     |  |      |  |      |  |      |  |      |        |      |   |            |   |       |   |           |  |   |      
|2003 Senior Convertible Notes (6.0%) (USD) |  |     |  |     |  |     |  | $    | 20,000 |      |  |            |  |       | $ | 20,000    |  | $ | 9,682



The convertible debt
instruments included in the above table have been classified on our balance sheet as of September 30, 2005 as current liabilities, because at that time we may have become obligated to redeem the 2003 Senior Convertible Notes prior to the
one-year anniversary of September 30, 2005.



We maintain
an investment portfolio of money market funds and auction rate securities. The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk. We currently do not hedge
interest rate exposure. Because of the short-term maturities of our investments, we do not believe that a change in interest rates would have a significant negative impact on the value of our investment portfolio.



The primary objective of our investment activities is to preserve principal
while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in investments supported by debt instruments of the U.S. Government and its agencies, bank obligations and
high-quality corporate issuers, and, by policy, restrict our exposure to any single corporate issuer by imposing concentration limits. To minimize the exposure due to adverse shifts in interest rates, we maintain investments at an average maturity
of generally less than three months.



|Item 4. | Controls and Procedures
|------- | -----------------------



In the Original Report, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by the Quarterly
Report, our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) or 15d-15(e) of the Exchange Act) were effective. This conclusion was reached after our Chief Executive Officer and Chief Financial Officer evaluated our
disclosure controls and procedures as of the end of the period covered by the Quarterly Report, as required by paragraph (b) of Rules 13a-15 or 15d-15 of the Exchange Act.



However, in connection with preparing the restated consolidated financial statements included in the Amendment, our Chief
Executive Officer and Chief Financial Officer further evaluated our disclosure controls and procedures as of the end of the period covered by the Quarterly Report and concluded that such disclosure controls and procedures were ineffective because in
the Original Report we erroneously accounted for certain of our current-portion of long-term indebtedness and other liabilities (including trade payables and accrued liabilities) as long-term liabilities, the supplemental required disclosures
regarding our foreign subsidiarys liabilities was incorrectly reported and our accrued interest payable was incorrectly reported due to our failure to reflect the issuance of common stock in lieu of interest on our 2003 Senior Convertible
Notes during the second quarter of 2005 which has a roll forward impact on the third quarter of 2005 and an adjustment due to an excess accrual. Management is currently evaluating the remediation steps necessary to make our disclosure controls and
procedures effective and we expect to implement the remediation steps by the end of the year.



As part of the preparation of the restated consolidated financial statements included in this Amendment, our Chief Executive Officer and our Chief Financial Officer identified certain deficiencies in the
Companys internal control over financial reporting related to (i) its system of entry of certain types of transactions into the general and subsidiary ledgers, and (ii) the timely reconciliation of general ledger balance sheet accounts to the
appropriate underlying subsidiary records. Some or all of these deficiencies may be a material weakness. As a result of these deficiencies, we have reclassified certain of our long-term liabilities as current liabilities and restated our accrued
interest payable to reflect the issuance of common stock in lieu of interest on our Senior Convertible Notes and an adjustment due to an excess accrual.



During the quarter ended September 30, 2005, there was not any change in our internal control over financial reporting identified in connection with the
evaluation required by paragraph (d) of Rules 13a-15 or 15d-15 of the Exchange Act that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. However, management and the Audit Committee
are currently evaluating the remediation steps necessary to address the significant deficiencies and/or material weakness in our internal control over financial reporting and we expect to implement the remediation steps by the end of this year.



20



---

##### Table of Contents

Part II - Other Information





|Item 6. | Exhibits
|------- | --------



|     |  |                                                                                                                              
|---- |  | -----------------------------------------------------------------------------------------------------------------------------
|     | 
|31.1 |  | Certification by Patrick T. Mooney, M.D., Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|     | 
|31.2 |  | Certification by James F. Smith, Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.         
|     | 
|32.1 |  | Certification by Patrick T. Mooney, M.D., Chief Executive Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|     | 
|32.2 |  | Certification by James F. Smith, Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.         



21



---

##### Table of Contents

Signatures



Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



|                        |  |  |  |                    |  |                                |  |                                                  
|----------------------- |  |  |  | ------------------ |  | ------------------------------ |  | -------------------------------------------------
|                        |  |  |  | APHTON CORPORATION
|                        |  |  | 
|Date: November 23, 2005 |  |  |  | By:                |  | /s/    PATRICK T. MOONEY,
M.D.
|                        |  |  |  |                    |  |                                |  | Patrick T. Mooney, M.D.                          
|                        |  |  |  |                    |  |                                |  | Chief Executive Officer and President            
|                        |  |  |  |                    |  |                                |  | (Principal Executive Officer)                    
|                        |  |  | 
|Date: November 23, 2005 |  |  |  | By:                |  | /s/    JAMES F. SMITH         
|                        |  |  |  |                    |  |                                |  | James F. Smith                                   
|                        |  |  |  |                    |  |                                |  | Senior Vice President and Chief Financial Officer
|                        |  |  |  |                    |  |                                |  | (Principal Financial Officer)                    



22



---

##### Table of Contents

Exhibit Index



|     |  |                                                                                                                              
|---- |  | -----------------------------------------------------------------------------------------------------------------------------
|     | 
|31.1 |  | Certification by Patrick T. Mooney, M.D., Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|     | 
|31.2 |  | Certification by James F. Smith, Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.         
|     | 
|32.1 |  | Certification by Patrick T. Mooney, M.D., Chief Executive Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|     | 
|32.2 |  | Certification by James F. Smith, Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002